The Biotech Reset: Capital Returns with Conditions
Author: Redwood Valuation Content Team
Published: March 30, 2026
Capital is moving again, and the IPO window is beginning to reopen. The shift is subtle but meaningful, and with real implications for biotech companies preparing to raise capital, pursue an exit, or establish defensible valuations.
For those waiting for biotech to "come back," the honest answer is that it already has. It just doesn't look like the market that existed in 2021. The era of abundant seed funding and frothy valuations attached to early scientific concepts has largely passed. What has returned is a more measured environment where investors are committing larger checks, but only to companies that can demonstrate credible progress and clear scientific direction.
That shift is not necessarily negative. In many ways, it clarifies the market. For founders, management teams, and the funds and advisors supporting them, understanding how investors are evaluating opportunities in this cycle is becoming increasingly important.
Capital Has Become More Selective
Biotech's share of total global venture funding has declined to its lowest levels in recent history [1], crowded out by the surge in AI investment, even as total dollar volumes have partially recovered from 2022–2023 lows, with healthcare and biotech receiving approximately $71.7 billion in 2025. [2] Deal volume has declined, and the time between financing rounds has lengthened across much of the sector. Early-stage companies, particularly those still in discovery or pre-IND phases, continue to face a difficult fundraising environment.
At the same time, a different pattern has emerged at the later stages of development. Companies with credible clinical data and well-defined development milestones are attracting a disproportionate share of new capital. [3] Rather than representing a contradiction, it reflects a redistribution of capital. Funding that once spread across hundreds of early bets is now concentrating in fewer companies that have already crossed key technical or clinical thresholds.
Investors increasingly view these opportunities as underwriting potential clinical outcomes rather than early hypotheses. Phase II and Phase III programs, differentiated platform technologies, and companies approaching meaningful data catalysts are attracting the most attention.
The implication is straightforward: Scientific promise alone rarely secures funding today. Demonstrable progress and well-defined development pathways matter far more than they did during the previous cycle.
The IPO Window Is Cracking Open
Public markets are beginning to reflect this gradual shift. After nearly two years of limited activity, biotech IPOs have begun to reappear, with 30 companies raising roughly $4 billion in 2024, up from $2.9 billion raised by 18 companies in 2023, though still well below the 10-year average of 54 annual offerings. [4] Post-offering performance remains uneven; the majority of 2024 listings finished the year below their offering prices, yet deal volume is recovering from its lows. The reopening remains narrow, and conditions are still difficult, but even cautious movement in public markets carries significance beyond the raw listing count.
Public market receptivity shapes the entire biotech capital ecosystem. When IPOs perform well, crossover investors typically return to the sector. As crossover capital re-engages, late-stage private rounds become more competitive, and valuation compression begins to ease.
The market has not fully reached that point, but the trajectory is changing. Companies that spent the past several years strengthening their clinical narratives and advancing development programs are now positioned to benefit from a capital market environment that is gradually becoming more receptive.
AI in Biotech: Powerful, but Not a Substitute for Biology
No discussion of the sector in 2025 would be complete without addressing AI. Computational biology platforms, predictive modeling tools, and AI-enabled target identification companies are attracting substantial investor attention. Many venture funds see these technologies as tools capable of improving capital efficiency and accelerating elements of the drug discovery process.
Yet even within this trend, investor discipline remains evident. Sophisticated investors are still underwriting the biology first. Basically, AI functions as an amplifier of scientific insight rather than the central asset itself. The companies attracting the strongest investor interest tend to combine several elements, such as:
• Validated mechanisms of action
• Proprietary datasets or defensible platform architectures
• Clearly defined regulatory pathways
Artificial intelligence can strengthen discovery and prioritization, but clinical validation remains the ultimate determinant of value.
What This Means for Biotech Companies
The companies navigating today's market most successfully tend to approach the environment with a different mindset than in previous cycles. Rather than assuming capital will eventually appear, they build their strategy around the realities of a more selective funding landscape.
A common thread among these companies is clarity around milestones. Instead of presenting broad long-term ambitions, management teams are defining precise inflection points such as what data will be generated, when those results are expected, and how much capital is required to reach them. Investors are increasingly modeling clinical trial design risk and capital runway sensitivity as part of diligence, so companies that can map a credible path from one milestone to the next tend to inspire greater confidence.
Valuation has also become a more strategic consideration. As crossover investors cautiously re-enter the sector and late-stage rounds regain momentum, the credibility of a company's valuation can materially influence whether a financing proceeds. For pre-revenue biotech companies, where intellectual property, platform risk, and limited comparable peers complicate traditional benchmarking, valuation often requires careful analysis of the underlying science, development pathway, and potential market opportunity. Simplified approaches rarely withstand investor scrutiny.
Perhaps most importantly, the balance between narrative and evidence has shifted. Biotech has always depended on compelling scientific stories, but today's investors are placing greater emphasis on measurable progress. Due diligence is deeper, the questions are more technical, and differentiation increasingly needs to be demonstrated through data rather than described through vision alone.
A Market Moving From Freeze to Selectivity
Biotech has not returned to the surge that defined the early part of the decade. Instead, what's emerging is a more selective market, where capital is beginning to move again, but with greater scrutiny.
Venture funding is stabilizing, public markets are cautiously reopening for the strongest companies, and AI-enabled research platforms are expanding the tools of discovery. At the same time, investors remain focused on scientific validation, credible data, and disciplined execution. As the sector moves beyond the risk-off freeze of the past two years, preparation matters. Companies with credible clinical data, clearly sequenced milestones, and disciplined capital strategies are best positioned to benefit.
Biotech may not be booming again yet. Still, the sector is active, and selectivity has often been where durable value begins.
[1] “Biotech Share Of U.S. Funding Hits Lowest Point In Crunchbase History,” Crunchbase News, Sept. 29, 2025. https://news.crunchbase.com/venture/biotech-us-funding-share-lowest-2025/
[2] “Global Venture Funding Posts Third-Largest Year On Record In 2025,” Crunchbase News, Jan. 2026. https://news.crunchbase.com/venture/funding-data-third-largest-year-2025/
[3] “The Biotech Landscape in 2025 and Beyond: Is a Rebound in the Making or Not?” DCAT Value Chain Insights, 2025. https://www.dcatvci.org/features/the-biotech-landscape-in-2025-and-beyond-is-a-rebound-in-the-making-or-not/
[4] “The Biotech Landscape in 2025 and Beyond: Is a Rebound in the Making or Not?” DCAT Value Chain Insights, 2025. https://www.dcatvci.org/features/the-biotech-landscape-in-2025-and-beyond-is-a-rebound-in-the-making-or-not/